

8th Annual Life Sciences Conference...Focused on Healthcare Today & Tomorrow

June 10-11, 2009
New York

Needham and Company's 8th Annual Life Sciences Conference was a high-impact forum for public and private institutional investors to hear the latest updates from senior management teams in the biotechnology, specialty pharma, and medical technology sectors. Over the two days, attendees participated in unplugged sessions, moderated presentations, and break-out discussions with companies as well as Meet-the-Expert panels with academic, clinical, and industry professionals.

Why this conference mattered in June 2009?

Biotechnology stock performance may remain challenging for the remainder of the year, as investors cycle out of the sector and away from defensive stocks. Yet we believe there may be opportunities for upside among certain smaller biotech companies with pivotal clinical or regulatory events this year. Increased interest in licensing and M&A activity between biotech and Big Pharma as well as consolidation among biotech companies will likely be seen for the remainder of 2009. The Specialty Pharmaceutical subsector has proven to be anything but special over the past 12 months, only marginally outperforming the S&P 500. A significant improvement in generic industry pricing power and a potential new crop of leadership to fill in the significant void of investable market cap in the group coupled with strong secular growth fundamentals suggest the generic companies remain positioned for substantial relative outperformance over the next 12 months. We expect a substantial rebound in our Aesthetic Technology and Sport Medicine groups as an economic recovery takes hold. For the most part, this group has strong balance sheets, neutral cash flows, and plenty of staying power to ride out the current downturn. We expect medtech stocks will be driven by catalysts, M&A activity, and market share shifts as core revenue and earnings growth is expected to slow for the industry in 2009. Molecular diagnostics companies may be well positioned for 2009, as they may provide both improve healthcare for patients and health economics for hospitals and payers.

•Over 800 1-on-1's Scheduled
•Over 500 institutional Attendees
•Over 75 VC/PE participants

Selected Biotech Company Presenters

Acadia Pharmaceuticals Inc. (ACAD)	Intuitive Surgical Inc. (ISRG)
Acceleron Pharma Inc. (PVT)	Islis Pharmaceuticals Inc. (ISIS)
Accuray Inc. (ARAY)	Kinetic Concepts Inc. (KCI)
Achillion Pharmaceuticals Inc. (ACHN)	MannKind Corp. (MNKD)
Advanced Biohealing (PVT)	Martek Biosciences Corp. (MATK)
Alexion Pharmaceuticals Inc. (ALXN)	Medarex Inc. (MEDX)
Alkermes Inc. (ALKS)	Medivation Inc. (MDVN)
Allos Therapeutics Inc. (ALTH)	Micrus Endovascular Corp. (MEND)
Alnylam Pharmaceuticals Inc. (ALNY)	MonoSolRx (PVT)
AMAG Pharmaceuticals Inc. (AMAG)	Myriad Genetics Inc. (MYGN)
Anacor Pharmaceuticals Inc. (PVT)	Natus Medical Inc. (BABY)
Analogic Corp. (ALOG)	Neurocrine Biosciences Inc. (NBIX)
Antares Pharma Inc. (AIS)	NeurogesX Inc. (NGSX)
Antisoma (AIOAF.PK)	NPS Pharmaceuticals (NPSP)
Arena Pharmaceuticals Inc. (ARNA)	NuVasive Inc. (NUVA)
ArQule Inc. (ARQL)	OmniGuide Inc. (PVT)
Avanir Pharmaceuticals (AVNR)	OncoGenex Pharmaceuticals (OGXI)
Aveo Pharmaceuticals (PVT)	Optimer Pharmaceuticals Inc. (OPTR)
Becton, Dickinson and Company (BDX)	OptiScan Biomedical Corp. (PVT)
Biodel Inc. (BIOD)	Pain Therapeutics Inc. (PTIE)
Biolase Technology Inc. (BLTI)	Palomar Medical Technologies Inc. (PMTI)
Cadence Pharmaceuticals Inc. (CADX)	Par Pharmaceutical Co Inc. (PRX)
Cardiac Science Corp. (CSCX)	Paratek Pharmaceuticals (PVT)
Celera Corp. (CRA)	Pharmacyclics Inc. (PCYC)
Celgene Corp. (CELG)	Pharmasset Inc. (VRUS)
Celldex Therapeutics Inc. (CLDX)	Poniard Pharmaceuticals Inc. (PARD)
Celsion Corp. (CLSN)	Progenics Pharmaceuticals Inc. (PGNX)
Cepheid (CPHD)	Protalix BioTherapeutics Inc. (PLX)
Coherex (PVT)	Qiagen NV (QGEN)
Conceptus Inc. (CPTS)	Regeneron Pharmaceuticals Inc. (REGN)
CONMED Corp. (CNMD)	Rosetta Genomics Inc. (ROSG)
Crucell NV (CRXL)	Sagent Pharmaceuticals (PVT)
Cubist Pharmaceuticals Inc. (CBST)	Sangamo BioSciences Inc. (SGMO)
Curis Inc. (CRIS)	Seattle Genetics Inc. (SGEN)
Cutera Inc. (CUTR)	Senomyx Inc. (SNMX)
Cyclacel Pharmaceuticals Inc. (CYCC)	SkinMedica (PVT)
Cynosure Inc. (CYNO)	Solta Medical Inc. (SLTM)
Cytokinetics Inc. (CYTK)	Sound Surgical Technologies LLC (PVT)
Cytori Therapeutics Inc. (CYTX)	Stereotaxis Inc. (STXS)
Delcath System Inc. (DCTH)	Sucampo Pharmaceuticals Inc. (SCMP)
Dendreon Corp. (DNDN)	Syneron Medical Ltd. (ELOS)
DepoMed Inc. (DEPO)	Teleflex Inc. (TFX)
Dyax Corp. (DYAX)	Telik Inc. (TELK)
Electro-Optical Sciences Inc. (MELA)	Theravance Inc. (THRX)
Emergent BioSolutions Inc. (EBS)	TomoTherapy Inc. (TOMO)
Entegion (PVT)	Transition Therapeutics Inc. (TTHI)
Gen-Probe Inc. (GPRO)	Trubion Pharmaceuticals Inc. (TRBN)
Geron Corp. (GERN)	Varian Medical Systems Inc. (VAR)
Given Imaging Ltd. (GIVN)	Vertex Pharmaceuticals Inc. (VRTX)
Hansen Medical Inc. (HNSN)	Vical Inc. (VACL)
Hi-Tech Pharmacal Co Inc. (HITK)	Vivus Inc. (VVUS)
Hologic Inc. (HOLX)	Watson Pharmaceuticals Inc. (WPI)
icad Inc. (ICAD)	Xoft Microtube Inc. (PVT)
Impax Laboratories Inc. (IPXL)	Xoma Ltd. (XOMA)
Inovio Biomedical Corp. (INO)	ZIOPHARM Oncology Inc. (ZIOP)
Inspire Pharmaceuticals (ISPH)	ZOLL Medical Corp. (ZOLL)
Integra LifeSciences Holdings Corp. (IART)	